论文部分内容阅读
AIM To assess dietary myo-inositol in reducing stem cell activation in colitis,and validate pβ-cateninS~(552) as a biomarker of recurrent dysplasia.METHODS We examined the effects of dietary myo-inositol treatment on inflammation,pβ-cateninS~(552) and p Akt levels by histology and western blot in IL-10-/-and dextran sodium sulfate-treated colitic mice. Additionally,we assessed nuclear pβ-cateninS~(552) in patients treated with myo-inositol in a clinical trial,and in patients with and without a history of colitis-induced dysplasia.RESULTS In mice,pβ-cateninS~(552) staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia(LGD),two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans,pβ-cateninS~(552) staining discriminated ulcerative colitis patients with a history of LGD from those with benign disease.CONCLUSION Enumerating crypts with increased numbers of pβ-cateninS~(552)-positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.
AIM To assess dietary myo-inositol in reducing stem cell activation in colitis, and validate pβ-catenin S ~ (552) as a biomarker of recurrent dysplasia. METHODS We examined the effects of dietary myo-inositol treatment on inflammation, pβ-cateninS ~ 552) and p Akt levels by histology and western blot in IL-10 - / - and dextran sodium sulfate-treated colitic mice. Additionally, we assessed nuclear pβ-cateninS ~ (552) in patients treated with myo-inositol in a clinical trial , and in patients with and without a history of colitis-induced dysplasia .RESULTS In mice, pβ-catenin S ~ (552) staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, pβ-cateninS ~ (552) a history of LGD from those with benign disease. CONCLUSION Enumerating crypts with increased numbers of pβ-catenin S ~ (552) -positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.